Sponsor: Exelixis, Inc.
Sponsor Study ID: XL092-001
Study Title: A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
CTO #: 103560
NCT Number: NCT03845166
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder; Breast; Kidney; Prostate
Study Objectives: This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.